Last updated on May 2018

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies


Brief description of study

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Clinical Study Identifier: NCT01442194

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Clermont, FL United States
0.89miles
  Connect »